Tisdag 26 November | 04:37:41 Europe / Stockholm
Svenska | English

BBS-Bioactive Bone Substitutes

Bifogade filer

Kursutveckling under dagen för detta pressmeddelande (EUR).

Likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

Tid*
2025-02-21 11:30 Bokslutskommuniké 2024
2024-08-09 - Kvartalsrapport 2024-Q2
2024-06-13 - Årsstämma
2024-05-02 - X-dag ordinarie utdelning BONEH 0.00 EUR
2024-02-26 - Bokslutskommuniké 2023
2023-10-23 - Extra Bolagsstämma 2023
2023-08-25 - Kvartalsrapport 2023-Q2
2023-05-02 - X-dag ordinarie utdelning BONEH 0.00 EUR
2023-04-28 - Årsstämma
2023-02-24 - Bokslutskommuniké 2022
2022-08-25 - Kvartalsrapport 2022-Q2
2022-04-29 - X-dag ordinarie utdelning BONEH 0.00 EUR
2022-04-28 - Årsstämma
2022-03-17 - Extra Bolagsstämma 2022
2022-02-24 - Bokslutskommuniké 2021
2021-08-25 - Kvartalsrapport 2021-Q2
2021-04-29 - X-dag ordinarie utdelning BONEH 0.00 EUR
2021-04-28 - Årsstämma
2021-02-24 - Bokslutskommuniké 2020
2020-08-31 - Kvartalsrapport 2020-Q2
2020-04-06 - X-dag ordinarie utdelning BONEH 0.00 EUR
2020-04-05 - Årsstämma
2020-03-20 - Bokslutskommuniké 2019
2019-08-30 - Kvartalsrapport 2019-Q2
2019-04-08 - X-dag ordinarie utdelning BONEH 0.00 EUR
2019-04-05 - Årsstämma
2018-08-30 - Kvartalsrapport 2018-Q2
2018-03-29 - Årsstämma

Beskrivning

LandFinland
ListaFirst North Finland
SektorHälsovård
IndustriMedicinteknik
BBS-Bioactive Bone Substitutes är verksamt inom medicinteknik. Bolaget designar, utvecklar och konstruerar biologiska implantat för patienter med benfel och läkningsbesvär. Bolagets lösningar vidaresäljs under varumärket Artebone och baseras på tricalciumfosfat (TCP) och benprotein, som stimulerar benläkningsprocessen. Bolaget grundades under 2003 och har sitt huvudkontor i Oulu.
BBS-Bioactive Bone Substitutes Plc: The complementary patent for the ARTEBONE® product has been granted in the USA
2024-09-11 14:00:00

BBS-Bioactive Bone Substitutes Plc | Company Release | September 11, 2024 at 15:00:00 EEST

The complementary patent for the ARTEBONE® product has been granted in the USA

BBS-Bioactive Bone Substitutes Plc (”Company”) has received an ”Issue Notification” from the United States Patent and Trademark Office that the Company’s complementary patent for “A METHOD FOR PREPARING A BONE PROTEIN PREPARATION AND A BONE PROTEIN PREPARATION” related to ARTEBONE®-product and its use in the treatment method will be granted on September 24, 2024 (”Issue Date”).

The Company announced on June 4, 2024, that the Claims of the complementary patent application for the ARTEBONE® product have been approved.

This is the second supplementary patent that the Company has applied for in the USA. Patents in the USA have previously been announced:

DateRelease
June 4, 2024Claims of the complementary patent application for the ARTEBONE® product have been approved in the USA
January 11, 2022US Patent for the Manufacture of ARTEBONE® product
November 17, 2021Claims of the patent application for the manufacturing of the ARTEBONE® product have been approved in the USA
April 7, 2020The patent regarding the product ARTEBONE® has been granted in the USA

.

For more information, please contact:
Juliusz Rakowski, CEO
+358 50 448 5132
juliusz.rakowski@bbs-artebone.fi

Certified Advisor:
Nordic Certified Adviser AB,
+46 70 551 67 29,
info@certifiedadviser.se

Distribution
Nasdaq Helsinki
https://www.bbs-artebone.fi/

BBS in brief
BBS -Bioactive Bone Substitutes Plc is an orthobiology company that started its operations in 2003. We have developed a new product for the treatment of complex bone fractures and bone healing issues. Our goal is to provide next-generation medical products for the treatment of bone injuries in orthopedic surgery. In the pharmaceutical industry, the development and research work require perseverance and courage to innovate. We have a track record of over 20 years in this field. Our company is characterized by expertise, innovation, and dedicated employees who are passionate about their work. Our first developed product, ARTEBONE® Paste, is in the final stages of the CE marking process to enable its commercialization in the EU market. We are based in Oulu with a medical manufacturing facility in Reisjärvi, holding a manufacturing license. The company's headquarters are in Oulu, and we employ over 20 people.

BBS has been listed on Nasdaq First North Growth Market Finland since February 2018.

More information: www.bbs-artebone.fi

Attachments
BBS-Bioactive Bone Substitutes Plc: The complementary patent for the ARTEBONE® product has been granted in the USA

Källa MFN
Enter your email address and you will get a mail for verification you subscription to content on this page and filter


Select the time zone location for site wide time

Europe
London
Oslo
Stockholm
Helsinki

America
New York / Eastern
Chicago / Central
Los Angeles / Western

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden